Merck Sharp + Dohme Corp.

Msd K.k.

Hisaki Kojima

Shinji Kato

Yaling Wang

Makoto Ishikawa

Masashi Kawasaki

Nobuaki Nonoyama

Steven A Weissman

Yuji Haga

Robert Wenslow

Taketo Ikeno

Fuyuki Yamamoto

Aaron J Moment

Russell R Ferlita

Sachin Lohani

Nobuya Satake

Shuntaro Furukawa

Wataru Minagawa

Naotaka Sawada

Keisuke Kamei

Kazuki Shigemori

The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2'-methyl-2&#x2032;,3&#x2032;-dihydro-1&#x2032;H-spiro[cyclopropane-1,4&#x2032;-isoquinolin]-7&#x2032;-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.

Process for producing bicycloaniline derivatives

The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4&#x2032;-carboxamide and novel salts, hydrates and polymorphs thereof.

Synthesis and crystalline forms of NPY5 antagonist

Growing community of inventors

Nagoya, Japan

Hisaki Kojima